Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood

Forensic Science International

Volumn 135, Issue 1, 2003, Pages 9-15

  Levo, Antti ^a   Koski, Anna ^a   Ojanperä, Ilkka ^a   Vuori, Erkki ^a   Sajantila, Antti ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CYP2D6 gene; Pharmacogenetics; SNP analysis; Tramadol

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLITE; N NORTRAMADOL; O NORTRAMADOL; TRAMADOL; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 0043127371     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0379-0738(03)00159-2     Document Type: Article

References (27)

1. Meyer U.A., Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37:1997;269-296.
2. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 286(5439):1999;487-491.
3. Ingelman-Sundberg M., Oscarson M., McLellan R.A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci. 20(8):1999;342-349.
4. Xie H.-G., Kim R.B., Wood A.J.J., Stein C.M. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41:2001;815-850.
5. Daly A.K., Brockmöller J., Broly F., Eichelbaum M., Evans W.E., Gonzalez F.J., Huang J.D., Idle J.R., Ingelman-Sundberg M., Ishizaki T., Jacqz-Aigrain E., Meyer U.A., Nebert D.W., Steen V.M., Wolf C.R., Zanger U.M. Nomenclature for human CYP2D6 alleles. Pharmacogenetics. 6(3):1996;193-210.
6. Sachse C., Brockmöller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60(2):1997;284-295.
7. Løvlie R., Daly A.K., Molven A., Idle J.R., Steen V.M. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 392(1):1996;30-34.
8. Steen V.M., Anreassen O.A., Daly A.K., Tefre T., Børresen A.-L., Idle J.R., Gulbrandsen A.-K. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics. 5(4):1995;215-223.
9. Daly A.K., Fairbrother K.S., Andreassen O.A., London S.J., Idle J.R., Steen V.M. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics. 6(4):1996;319-328.
10. Johansson I., Lundqvist E., Dahl M.-L., Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics. 6(4):1996;351-355.
11. Stüven T., Griese E.-U., Kroemer H.K., Eichelbaum M., Zanger U.M. Rapid detection of CYP2D6 null alleles by long distance and multiplex-polymerase chain reaction. Pharmacogenetics. 6(5):1996;417-421.
12. Rasanen I., Ojanperä I., Vartiovaara J., Vuori E., Sunila P. The advantage of dual-column approach and retention indices combined with refined reporting in gas chromatographic drug screening. J. High Resolut. Chromatogr. 19(6):1996;313-321.
13. Scott L.J., Perry C.M. Tramadol. A review of its use in perioperative pain. Drugs. 60(1):2000;139-176.
14. Paar W.D., Poche S., Gerloff J., Dengler H.J. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur. J. Clin. Pharmacol. 53(3-4):1997;235-239.
15. Subrahmanyam V., Renwick A.B., Walters D.G., Young P.J., Price R.J., Tonelli A.P., Lake B.G. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab. Dispos. 29(8):2001;1146-1155.
16. S. Rendic, Human P450 Metabolism Database, 2001 (http://www.gentest.com/human_p450_database/).
17. M. Oscarson, M. Ingelman-Sundberg, A.K. Daly, D.W. Nebert, Human cytochrome P450 (CYP) Allele Nomenclature Committee, 2001 (http://www.imm.ki.se/CYPalleles/).
18. Marez D., Legrand M., Sabbagh N., Guidice J.M., Spire C., Lafitte J.J., Meyer U.A., Broly F. Polymorphism of the P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 7(3):1997;193-202.
19. Lee C.R., McTavish D., Sorkin E.M. Tramadol A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs. 46(2):1993;313-340.
20. Alvan G., Bertilsson L., Dahl M.-L., Ingelman-Sundberg M., Sjöqvist F. Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation. Drug Metab. Dispos. 29(4 Pt 2):2001;580-585.
21. Nebert D.W. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am. J. Hum. Genet. 60(2):1997;265-271.
22. Sallee F.R., DeVane C.L., Ferrell R.E. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J. Child Adolesc. Psychopharmacol. 10(1):2000;27-34.
23. Druid H., Holmgren P., Carlsson B., Ahlner J. Cytochrome P450 2D6 (CYP2D6) genotyping on post-mortem blood as a supplementary tool for interpretation of forensic toxicologal results. Forensic Sci. Int. 99(1):1999;25-34.
24. Bailey B., Daneman R., Daneman N., Mayer J.M., Koren G. Discrepancy between CYP2D6 phenotype and genotype derived from post-mortem dextromethorphan blood level. Forensic Sci. Int. 110(1):2000;61-70.
25. Öhberg A., Vuori E., Ojanperä I., Lönnqvist J. Alcohol and drugs in suicides. Br. J. Psychiatr. 169(1):1996;75-80.
26. Jackson P.R., Tucker G.T., Lennard M.S., Woods H.F. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br. J. Clin. Pharmacol. 22(5):1986;541-550.
27. ICD-10. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, WHO, Geneva, Switzerland, 1992.